Home » Our business

Debio 0617

Debio 0617 is a pre-clinical project developing a small molecule inhibiting an undisclosed target for the treatment of cancer.

Press Releases

13 September 2010

Debiopharm Group™ and Aurigene nominate development candidate

20 November 2008

Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway

13 July 2006

Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group